These authors contributed equally to this work.
Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain
Article first published online: 27 AUG 2013
Copyright © 2013 EMBO Molecular Medicine
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 10, pages 1484–1501, October 2013
How to Cite
Odolczyk, N., Fritsch, J., Norez, C., Servel, N., da Cunha, M. F., Bitam, S., Kupniewska, A., Wiszniewski, L., Colas, J., Tarnowski, K., Tondelier, D., Roldan, A., Saussereau, E. L., Melin-Heschel, P., Wieczorek, G., Lukacs, G. L., Dadlez, M., Faure, G., Herrmann, H., Ollero, M., Becq, F., Zielenkiewicz, P. and Edelman, A. (2013), Discovery of novel potent ΔF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med, 5: 1484–1501. doi: 10.1002/emmm.201302699
See accompanying article 10.1002/emmm.201303301
- Issue published online: 2 OCT 2013
- Article first published online: 27 AUG 2013
- Manuscript Accepted: 19 JUL 2013
- Manuscript Revised: 18 JUL 2013
- Manuscript Received: 19 MAR 2013
- European Commission, FP6-2003-Lifescihealth-I program
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
|emmm201302699.reviewer_comments.pdf||PDF document||520K||Review Process File|
Figure S1. Two binding pockets on the ΔF508-NBD1 surface.
Figure S2. A. Representative iodide efflux curves obtained in HeLa cells stably transfected with WT-CFTR.
Figure S3. The local analysis of WT-NBD1 trajectory only in the areas of two binding regions.
Figure S4. A–D. Histogram of deuterium uptakes in ΔF508-NBD1 in the presence of compounds 118208 or 407882.
Figure S5. A–D. Differences in deuterium uptake between ΔF508-NBD1 incubated with 118208 (A)/(B) or 4078823 (C)/(D) compounds %Ddrug − %Dcontrol (% deuteriumdrug − % deuteriumcontrol).
Figure S6. A–D. Differences in deuterium uptake between WT-NBD1 incubated with 118208 (A)/(B) or 4078823 (C)/(D) compounds %Ddrug − %Dcontrol (%deuteriumdrug − %deuteriumcontrol).
Figure S7. The full-length CFTR model coordinates have been adopted from Mornon et al (2008).
Table S1. Compounds selected by virtual screening procedure for experimental tests.
Table S2. Virtual screening results from each scoring function for selected ligands.
Table S3. Peptides with diminished HDex rates in the presence of correcting compounds.
Table S4. Peptides of WT-NBD1 with diminished HDex rates in the presence of correcting compounds.
Table S5. DynamX criteria for filtering the list of ΔF508-NBD1 peptides from PLGS program.
Table S6. Parameters for processing MS spectras by DynamX program.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.